AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05299424
Drug: CM336_group 6a
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 6b
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 7
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 8a
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 8b
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_group 9
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Trial: NCT05299424
Drug: CM336_RP2D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
Trial: NCT05462262
Drug: Intensive lipid-lowering control
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
Trial: NCT05462262
Drug: Moderate-intensity lipid-lowering control
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
Trial: NCT06381791
Drug: Placebo oral solution
RxNorm normalized name: Placebo Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg of Placebo oral solution
Trial: NCT06381960
Drug: Fuzhengquye Fang Recipe simulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: Fuzhengquye Fang Recipe simulant, which was prepared into control group placebo drug according to 5% of the drug content in the treatment group. Combined with basic chemotherapy after lung cancer.
Trial: NCT06275958
Drug: Doublet Chemotherapy, Standard Dose (100%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
Trial: NCT06275958
Drug: Doublet Chemotherapy, Dose-reduced (75%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
Trial: NCT06275958
Drug: Monotherapy, Standard Dose (100%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
Trial: NCT06275958
Drug: Monotherapy, Dose-reduced (75%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75% of:~- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
Trial: NCT04650893
Drug: Intravenous Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
Trial: NCT04650893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT05487391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06160167
Drug: IMiD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with MM treated with IMiDs
Trial: NCT06160167
Drug: No IMiD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with MM not treated with IMiDs
Trial: NCT06160167
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with MM treated with systemic therapy
Trial: NCT05670184
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
Trial: NCT05183984
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period
Trial: NCT05205837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug - Placebo Intramuscular injektion - placebo
Trial: NCT05462496
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3
Trial: NCT04571580
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intracoronary infusion with normal saline
Trial: NCT06490263
Drug: Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.
Trial: NCT06490263
Drug: Mulberry Twig Alkaloids Tablets with single dose in healthy subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parts Two: Administered by swallowing after meals with four distinct dosage groups.
Trial: NCT06490263
Drug: Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
Trial: NCT06434493
Drug: Concurrent oral capecitabine chemotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days
Trial: NCT06076213
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT05158699
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac topical eye drops (Yellox)
Trial: NCT05158699
Drug: Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
RxNorm normalized name: ketorolac-phenylephrine ophthalmic 0.3%-1% intraocular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
Trial: NCT04946370
Drug: Androgen receptor pathway inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.
Trial: NCT06554639
Drug: MK-5684
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via oral tablet per dosing regimen.
Trial: NCT06643078
Drug: HL231 Solution for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg, treatment period; 52-weeks fixed dose.
Trial: NCT06643078
Drug: Ultibro 110μg/50 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultibro capsule for inhalation once per day via Breezhaler, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, treatment period; 52-weeks fixed dose.
Trial: NCT06637761
Drug: NeoMTA2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-active bio-ceramic mineral trioxide aggregate
Trial: NCT06640777
Drug: Supportive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
Trial: NCT06641960
Drug: Probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction with probiotic lozenges.
Trial: NCT06639282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
Trial: NCT06640309
Drug: Nicotinamide Tablet
RxNorm normalized name: Nicotinamide Tablet
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide is anti-inflammatory and antioxidant.
Trial: NCT05837897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab placebo-matching IV infusion
Trial: NCT05152485
Drug: BIIB104 Reference Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT05152485
Drug: BIIB104 Test Formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT04794504
Drug: Botox 100 UNT Injection
RxNorm normalized name: Botox 100 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox will be injected intramuscularly into the masseter and temporalis muscles bilaterally to investigate if it can supplement postoperative analgesia in orthognathic surgery patients
Trial: NCT05102448
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Methotrexate (15mg each week) for 12 months~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria.
Trial: NCT06014801
Drug: Dialysate fluid, Filtration replacement fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of continuous hemodialysis and/or hemofiltration
Trial: NCT06454110
Drug: NM8074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
Trial: NCT05397665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral suspension
Trial: NCT05087342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo will be given to the control group per the schedule outlined in the armed description.
Trial: NCT06403735
Drug: QLC1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
Trial: NCT05547542
Drug: [11C]-LY2795050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection
Trial: NCT06675734
Drug: diclofenac sodium solution
RxNorm normalized name: Diclofenac Sodium Solution
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The experimental group consisted of patients in whom diclofenac sodium was administered IM and the control group consisted of patients in whom diclofenac sodium was administered orally only.
Trial: NCT06690840
Drug: Atezolizumab in combination with Cyclophosphamide and Vinorelbine
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles
Trial: NCT05147493
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
Trial: NCT06570369
Drug: SP-624
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, once daily for 2 weeks
Trial: NCT06570369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, once daily for 2 weeks
Trial: NCT06365502
Drug: Guideline-directed medical treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All individuals will receive guideline-directed medical treatment.
Trial: NCT05708690
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
Trial: NCT06570538
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil 2.0 μg/kg, 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
Trial: NCT05603182
Drug: PRA052
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRA052
Trial: NCT05704088
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: randomized control trial, control group will receive placebo tablets
Trial: NCT04714177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
Trial: NCT04198649
Drug: Non-surgical periodontal treatment and azithromycin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions
Trial: NCT06564714
Drug: Usual routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen is initiated only when acute spasticity is deemed problematic.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response.
Trial: NCT05341843
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
Trial: NCT05412979
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine
Trial: NCT06638034
Drug: 68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
Trial: NCT04904913
Drug: IBI362
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI362 administered subcutaneously (SC) once a week.
Trial: NCT04588792
Drug: Nebulized Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered by nebulization through the ventilator circuit
Trial: NCT05838287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Pioglitazone
Trial: NCT06641661
Drug: Hybutimibe 10mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybutimibe was added to the conventional treatment
Trial: NCT06277219
Drug: LAT010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAT010 monotherapy
Trial: NCT06277219
Drug: LAT010 + ICI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAT010 combination with PD-1 inhibitor
Trial: NCT06570980
Drug: sulfonylurease with metformin, DPP4 inhibitors with Metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemic agents
Trial: NCT05039489
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
Trial: NCT05972785
Drug: Calcium channel blocker
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with ATC code C08 will be categorised as calcium channel blockers.
Trial: NCT05972785
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with ATC code C07 will be categorised as beta-blockers.
Trial: NCT05972785
Drug: Diuretic
RxNorm normalized name: Diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with ATC code C03 will be categorised as diuretics.
Trial: NCT05972785
Drug: None AHT
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: None AHT
Trial: NCT06114628
Drug: GSK3036656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dosage of 20mg.
Trial: NCT04816721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension to match EDP-938
Trial: NCT06643260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive control
Trial: NCT06569355
Drug: VCT220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A small molecule GLP-1R agonist tablet, orally administration, once daily
Trial: NCT06569355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05618925
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate and has the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1.
Trial: NCT06673654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
Trial: NCT06433921
Drug: Salbutamol HFA-152a
RxNorm normalized name: HYDROFLUOROCARBON 152A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
Trial: NCT06433921
Drug: Salbutamol HFA-134a
RxNorm normalized name: HYDROFLUOROCARBON 134A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.